Childhood asthma exerts a costly toll on individuals, families, and society. It is a complex and heterogeneous disease that consists of several clinical phenotypes. It is increasingly clear that this complex disease has numerous variants with differing underlying pathophysiologies. Asthma phenotyping directs attention at defining subgroups of asthma with distinct risk factors, comorbidities, triggers, and responses to treatment. To capture these diverse underlying pathophysiologies and their cognate mechanisms, the term “endotype” recently was suggested to define distinct mechanistic or pathophysiological subtypes of asthma.1,2 Currently, asthma phenotyping and endotyping are not part of the standard assessment, evaluation, and treatment of childhood asthma. As will become evident, this needs to change.